Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy - PubMed

Case Reports

Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy

R J Buckanovich et al. Ann Hematol. 2002 Jul.

Abstract

Nonmyeloablative allogeneic stem cell transplantation (NMASCT) can be used to exploit the graft-versus-tumor (GVT) potential of allogeneic donor cells in the setting of reduced conditioning regimen toxicity. This approach is particularly attractive for patients who have received extensive prior therapy and are poor candidates for traditional allogeneic stem cell transplantation. However, toxicity in heavily pretreated patients remains uncertain. Additional immunosuppression in already immunocompromised patients may result in unexpected toxicity. We report a case of probable progressive multifocal leukoencephalopathy (PML) responsive to interleukin-2 (IL-2) following a NMASCT in a 29-year-old woman with relapsed Hodgkin's lymphoma. The patient developed severe neurological symptoms approximately 6 weeks following NMASCT associated with low CD4+ cell counts and magnetic resonance imaging (MRI) was consistent with PML. IL-2 therapy resulted in increasing CD4+ counts and progressive resolution of neurological symptoms. Disruption of IL-2 therapy led to neurological deterioration, which responded to reinstitution of IL-2 therapy. The patient's lymphoma initially progressed following NMASCT, but has responded to donor leukocyte infusions (DLI). This case reiterates the potent GVT potential of NMASCT in patients with Hodgkin's disease. However, it demonstrates the potential for severe complications related to immunosuppression, especially in heavily pretreated patients. The toxicity after NMASCT should not be understated and will need to be explored further.

Similar articles

• Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation.

  Ruiz-Argüelles GJ, López-Martínez B, López-Ariza B. Ruiz-Argüelles GJ, et al. Arch Med Res. 2003 May-Jun;34(3):242-5. doi: 10.1016/S0188-4409(03)00005-5. Arch Med Res. 2003. PMID: 14567405

• Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation.

  Tamaki H, Kawakami M, Ikegame K, Iio K, Harada Y, Hatanaka K, Oka Y, Kawase I, Ogawa H. Tamaki H, et al. Int J Hematol. 2004 Oct;80(3):291-4. doi: 10.1532/ijh97.04084. Int J Hematol. 2004. PMID: 15540907

• Progressive multifocal leukoencephalopathy: a rare infectious complication following allogeneic hematopoietic cell transplantation (HCT).

  Kaufman GP, Aksamit AJ, Klein CJ, Yi ES, Delone DR, Litzow MR. Kaufman GP, et al. Eur J Haematol. 2014 Jan;92(1):83-7. doi: 10.1111/ejh.12208. Epub 2013 Oct 25. Eur J Haematol. 2014. PMID: 24118404

• Progressive multifocal leukoencephalopathy due to John Cunningham (JC) virus following allogeneic haematopoietic cell transplantation.

  Lam W, Al-Shaibani Z, Kumar D, Viswabandya A, Thyagu S, Michelis FV, Kim DD, Lipton JH, Messner HA, Deotare U. Lam W, et al. Antivir Ther. 2017;22(8):721-725. doi: 10.3851/IMP3162. Antivir Ther. 2017. PMID: 28362268 Review.

Cited by

• Long-term outcome of progressive multifocal leukoencephalopathy with recombinant interleukin-2 treatment and an associated increase in the number of HPyV-2-specific T-cells: a case report.

  Hoff FW, Rolwes J, Hardeman PA, Perkins M, Major EO, Douek D, Collins RH Jr, Greenberg BM. Hoff FW, et al. Ther Adv Hematol. 2023 Oct 9;14:20406207231201721. doi: 10.1177/20406207231201721. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37822572 Free PMC article.

• Innovative therapeutic concepts of progressive multifocal leukoencephalopathy.

  Möhn N, Grote-Levi L, Hopfner F, Eiz-Vesper B, Maecker-Kolhoff B, Warnke C, Sühs KW, Wattjes MP, Höglinger GU, Skripuletz T. Möhn N, et al. J Neurol. 2022 May;269(5):2403-2413. doi: 10.1007/s00415-021-10952-5. Epub 2022 Jan 7. J Neurol. 2022. PMID: 34994851 Free PMC article. Review.

• Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosis.

  Dohrn MF, Ellrichmann G, Pjontek R, Lukas C, Panse J, Gold R, Schulz JB, Gess B, Tauber SC. Dohrn MF, et al. Ther Adv Neurol Disord. 2021 Jul 31;14:17562864211035543. doi: 10.1177/17562864211035543. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34377151 Free PMC article.

• Progressive multifocal leukoencephalopathy in HIV-1 infection.

  Cinque P, Koralnik IJ, Gerevini S, Miro JM, Price RW. Cinque P, et al. Lancet Infect Dis. 2009 Oct;9(10):625-36. doi: 10.1016/S1473-3099(09)70226-9. Lancet Infect Dis. 2009. PMID: 19778765 Free PMC article. Review.

• Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

  Tavazzi E, White MK, Khalili K. Tavazzi E, et al. Rev Med Virol. 2012 Jan;22(1):18-32. doi: 10.1002/rmv.710. Epub 2011 Sep 21. Rev Med Virol. 2012. PMID: 21936015 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program